103 Alliance UniChem Plc 42 ACQUISITIONS CONTINUED Purchase of businesses continued Retail Book Provisional value at Fair value fair value at acquisition adjustments acquisition Assets acquired at book and provisional fair value million million million Intangible assets retail pharmacy licences 24.7 69.2 93.9 Property, plant and equipment 6.7 0.2 6.5 Inventories 11.2 0.5 10.7 Trade and other receivables 9.2 0.2 9.4 Borrowings bank overdrafts 2.5 2.5 bank loans 2.5 2.5 Trade and other payables 10.7 10.7 Current corporate tax liabilities 3.3 0.1 3.4 Deferred tax liabilities 20.6 20.6 Net assets acquired 32.8 48.0 80.8 Consideration paid million Cash 117.3 Deferred consideration movement 0.3 117.0 Purchased goodwill 36.2 Retail acquisitions comprised the acquisition of 83 pharmacies in the UK, Norway and The Netherlands.
43 DISPOSALS Disposal of businesses During the year the Group disposed of 51% of its interest in Alliance UniChem Farmacutica A. G. its entire interest in Elvetec in France and a number of other minor interests.
The proceeds received for these transactions were 32.5 million.
Within the balance sheets of the businesses disposed were net overdrafts of 66.2 million.
In addition, the Group received deferred consideration of 12.0 million arising from the disposal of non-core UK businesses in 2004.
Disposal of investments in associates As described in note 42, during the year the Group restructured its relationship with Galenica A. G..
The transaction was settled on a net basis and resulted in a net cash inflow to the Group of 15.7 million.
This comprised 8.6 million of net proceeds, 41.4 million of associate loans being repaid and, in respect of the acquired companies, 2.0 million of net cash and 36.3 million of borrowings were held in the acquired balance sheets.
In addition, the Group disposed of a minor associated undertaking for disposal proceeds of 0.1 million.
Disposal of available-for-sale investments During the first half of the year, the Group disposed of its investment in Sanacorp Pharmahandel A. G.. 44 SHARE-BASED PAYMENTS The Group issues equity settled, share-based payments to certain employees.
Equity settled share-based payments are measured at fair value at the date of grant.
The fair value determined at the grant date of the equity settled, share-based payments is expensed on a straight-line basis over the vesting period, based on the Groups estimate of shares that will eventually vest.
Fair value is measured by use of an actuarial binomial model.
The model includes adjustments, based on managements best estimate, for the effects of exercise restrictions, behavioural considerations and expected dividend payments.
The option life is derived by the model based on these assumptions and the other assumptions identified below.
The total expense included within profit from operations in respect of share-based payments was 5.3 million 2004 2.2 million.
104 Alliance UniChem Plc Notes to the financial statements for the year ended 31 December 2005 44 SHARE-BASED PAYMENTS CONTINUED Further details of the different types of share-based payments are as follows: Discretionary 1997 Share Option Scheme The Group operates a discretionary share option scheme for certain employees whereby options become exercisable on the achievement of certain financial earnings per share performance targets by the Group.
Options granted under the scheme since May 2003 have no retesting of performance measures and have a fixed performance period being a defined three year period made up of three consecutive accounting periods.
This period commences on 1 January of the year of the award.
The option price is set at the market price of the Companys shares.
For those share option awards which gave rise to an expense in the year, the assumptions used in the calculation of the fair values were as follows: Grant date 21 May 2003 19 March 2004 6 May 2005 19 May 2005 26 October 2005 Exercise price 489.0p 556.0p 810.5p 818.2p 759.2p Vesting period years 34 34 3 4 3 Contractual lifetime years 7 7 7 7 7 Expected volatility 28% 28% 26% 26% 26% Expected option life years 3.94.6 3.94.6 4.2 4.8 4.2 Risk free rate 3.9% 4.5%4.6% 4.6% 4.3% 4.6% Expected dividends expressed as a dividend yield 3.1% 3.1% 2.3% 2.3% 2.3% Fair value pence 117.1p121.3p 136.5p142.5p 206.4p 214.6p 193.3p The expected volatility is based on the historic volatility of the Companys share price over the expected life of the option.
The movement during the year of the total outstanding options in respect of the awards identified above is provided below.
The analysis of the outstanding options by award date at the beginning and the end of the year is provided in note 34.
Weighted average Number exercise price Outstanding at 1 January 2005 3,803,295 522.4p Granted 1,753,506 810.3p Lapsed 128,971 647.5p Exercised 159,000 520.2p Outstanding at 31 December 2005 5,268,830 615.2p None of the share options identified above as outstanding at 31 December 2005 had vested at that date.
Savings Related Scheme The Group provides UK employees with the ability to participate in the Groups Save As You Earn SAYE scheme which allows qualifying employees the opportunity to make regular savings over a fixed period of three, five or seven years.
These savings accumulate with interest at a guaranteed rate.
At the end of the savings contracts a bonus is added to the savings and participants have the option to use their savings to buy shares in Alliance UniChem Plc at a fixed price.
In common with other UK companies, the option price is set at a 20% discount to the market price of the Companys shares at the date of grant.
Exercise of an option is subject to continued employment.
For those share options issued under SAYE schemes which gave rise to an expense in the year, the assumptions used in the calculation of the fair values were as follows: Grant date 17 April 2003 6 April 2004 5 April 2005 Exercise price 337.0p 440.0p 589.5p Vesting period years 3, 5 or 7 3, 5 or 7 3, 5 or 7 Expected volatility 28% 28% 26% Expected option life years 3.77.7 3.77.7 3.67.5 Risk free rate 3.9%4.4% 4.7%4.9% 4.7% Expected dividends expressed as a dividend yield 3.3% 2.9% 2.4% Fair value 141.9p156.6p 202.5p225.8p 267.1p304.4p The expected volatility is based on the historic volatility of the Companys share price over the expected life of the option.
105 Alliance UniChem Plc 44 SHARE-BASED PAYMENTS CONTINUED Savings Related Scheme continued The movement during the year of the total outstanding options in respect of the schemes identified above is provided below.
Weighted average Number exercise price Outstanding at 1 January 2005 2,072,606 376.4p Granted 691,918 589.5p Lapsed 2,251 387.7p Forfeited 124,283 437.9p Cancelled 113,041 429.3p Exercised 11,565 364.0p Outstanding at 31 December 2005 2,513,384 429.7p None of the share options identified above as outstanding at 31 December 2005 had vested at that date.
Long-term incentive plan The long-term incentive plan is a discretionary arrangement under which allocations are made to executive Directors with the aim of rewarding them for creating shareholder value.
Each allocation takes the form of a non-binding statement of intent to make an award of a stated maximum amount following the end of a specified performance period.
The allocation is determined as a percentage of basic salary in the year that the performance period starts.
The amount of the award is dependent on the achievement of certain performance measures during the performance period that the remuneration committee believe are the most appropriate measure of the underlying performance of the Group.
The award takes the form of a right to acquire ordinary shares in the Company for a nominal sum within a period of ten years from the date of the award.
The number of shares will be determined by the market price of the Companys shares at the date of the award.
Further details are provided in the Board report on remuneration.
For those awards which gave rise to an expense in the year, the assumptions used in the calculation of the fair values were as follows: 2003 2004 2005 allocation allocation allocation Grant date 7 March 19 February 18 February 2003 2004 2005 Exercise price 0.001p 0.001p 0.001p Vesting period years 333 Possibility of ceasing employment before vesting 0% 0% 0% Expectation of meeting performance criteria 70.3% 70.3% 71.7% The movement during the year of the total outstanding allocations in respect of the awards identified above is provided below.
The analysis of the outstanding allocations by award date at the end of the year and the comparative year is provided in the Board report on remuneration.
Allocation Outstanding at 1 January 2005 2,493,331 Granted 2,425,000 Forfeited 521,666 Outstanding at 31 December 2005 4,396,665 None of the allocations identified above as outstanding at 31 December 2005 had vested at that date.
